William Tamborlane, MD
Professor Emeritus of PediatricsCards
Appointments
Contact Info
Pediatric Endocrinology & Diabetes
PO Box 208064
New Haven, CT 06520-8064
United States
About
Titles
Professor Emeritus of Pediatrics
Biography
William V. Tamborlane, MD, received his undergraduate BS degree from Georgetown University and was also a graduate of Georgetown University School of Medicine, where he completed his residency in pediatrics before going to Yale as a postdoctoral fellow in pediatric endocrinology. His scientific accomplishments over the past 45 years have established his international reputation as one of the most highly regarded clinical scientists in childhood diabetes and related disorders. He has published more than 1,000 original articles, chapters and reviews in the area of diabetes. Major accomplishments have included pioneering studies in the development of insulin pump therapy, direction of the Yale Center in the NIDDK-sponsored DCCT/EDIC and GRADE studies, and investigations of diabetes-induced defects in counterregulatory hormone responses to hypoglycemia. The prime focus of his work has been in patient-oriented studies in type 1 and type 2 diabetes and related metabolic and endocrine disorders. The hallmark of his research has been to overcome metabolic, physiologic and psychological obstacles to successful management of diabetes. Current research effort is focused on applying recent advances in diabetes technology towards the development of an artificial pancreas for individuals with type 1 diabetes and the study of new treatments of childhood obesity and type 2 diabetes. He is the recipient of many awards and honors and is frequently listed in publications of distinction, including American Men and Women of Science, The Best Doctors in America, America’s Top Doctors and America’s Top Pediatricians. In 2006 and 2011, he was awarded the Mary Tyler Moore and S. Robert Levine Award for Excellence in Clinical Research in Type 1 Diabetes by the Juvenile Diabetes Research Foundation. he has also received the 2009 Diabetes Technology Society’s Diabetes Technology Leadership Award, the 2010 American Diabetes Association Outstanding Physician Clinician Award, the 2014 National Award for Career Achievement and Contributions to Clinical, the Translational Science by ACRT/SCTS/AFMR, the 2014 Diabetes Prize for Achievement by the International Society for Pediatric and Adolescent and the 2017 American Diabetes Association award for Outstanding Achievement in Clinical Diabetes Research. He has served on the FDA’s Endocrine Advisory Board, on the National Board of Directors of the American Diabetes Association, was the first Steering Committee Chair of the Diabetes Research in Children Network, is the Founder and Chair of the Pediatric Diabetes Consortium and former Vice Chair (for Pediatrics) of the T1D Exchange Clinic Registry. He leads a multidisciplinary team of physicians, diabetes nurse educators, dieticians and social workers that care for more than 1000 children, adolescents and young adults with diabetes. He has also been the mentor of many young physician scientists in their training and career development in clinical research in diabetes.
Appointments
Pediatric Endocrinology & Diabetes
EmeritusPrimary
Other Departments & Organizations
- Diabetes Program
- Diabetes Research Center
- Fellowship Training
- MR Center
- Office of Research Services
- Pediatric Endocrinology & Diabetes
- Pediatrics
- Yale Ventures
Education & Training
- Fellow
- Medicine and Pediatrics, Yale University (1977)
- Chief Resident
- Georgetown University Hospital Washington DC (1975)
- Resident
- Georgetown University Hospital, Washington DC (1975)
- MD
- Georgetown University (1972)
Board Certifications
Pediatric Endocrinology
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 1986
Pediatrics
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 1978
Research
Overview
Dr. William Tamborlane studies diabetes and metabolism in children. He directs the Yale Center in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study and is the Principal Investigator in the Yale Center in the NIH-supported, multi-center GRADE study of type 2 diabetes. Dr. Tamborlane is Co-Program Director of the Combined Adult and Pediatric training grant in endocrinology/diabetes from the NIH/NIDDK, as well as Program Director of the Yale Pediatric Diabetes Career Development K12 program from NIH/NIDDK . He is Deputy Director of the Yale Center for Clinical Investigation that is transforming the support that is provided for clinical research across the entire medical center campus and the Director of the Translational Science Core of the Yale Diabetes Research Center. In April 2006 he received the prestigious Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation International at its annual meeting in Washington, D.C. In 2009 Dr. Tamborlane received the Diabetes Technology Society Leadership Award, in 2010 the American Diabetes Association Outstanding Clinician Physician in Diabetes Award, in 2014 he received the Career Achievement Award from the International Society for Pediatric and Adolescent Diabetes (ISPAD) and in 2017 he received the American Diabetes Association Award for Achievements in Clinical Diabetes Research. He is the author or co-author of more than 1,000 publications in diabetes and related disorders.
- continuous glucose monitoring studies
- insulin pump studies
- artificial pancreas studies
- pharmacokinetic and pharmacodynamic studies
- hypoglycemia studies
- pivotal trials for new drugs for youth with T2D and T1D
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Michelle Van Name, MD
James Dziura, MPH, PhD
Stuart Alan Weinzimer, MD
Jennifer Sherr, MD, PhD
Elizabeth Doyle, DNP, APRN, PNP (BC), CDE
Anisha Patel, DO
Diabetes Mellitus, Type 1
Insulin
Hypoglycemia
Diabetes Mellitus, Type 2
Glucose
Diabetes Mellitus
Publications
2024
1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials
BJORNSTAD P, DANNE T, TAMBORLANE W, KLINGENSMITH G, SCHUELER E, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S, LAFFEL L. 1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials. Diabetes 2024, 73 DOI: 10.2337/db24-1140-p.Peer-Reviewed Original ResearchConceptsDiabetic kidney diseaseKidney diseaseHoc analysisDiabetic kidney disease riskEarly diabetic kidney diseaseBaseline to weekImpact of empagliflozinCystatin C equationClinically relevant improvementNational Institute of DiabetesDigestive and Kidney DiseasesPost hoc analysisEGFR changeIncreased riskHyperfiltrationPubertal statusGlycemic controlEGFRC equationLong-term effectsPotential long-term effectsRelevant improvementNormofiltrationT2DHealthy youth
2023
1162-P: Promoting Career Development of Physicians Engaged in Type 1 Diabetes (T1D) Research—The New DiabDocs Multicenter National K12 Program
DASANI K, BISHOP F, GOLDEN S, LAFFEL L, MIRMIRA R, STECK A, TAMBORLANE W, WILLI S, MAAHS D, DIMEGLIO L. 1162-P: Promoting Career Development of Physicians Engaged in Type 1 Diabetes (T1D) Research—The New DiabDocs Multicenter National K12 Program. Diabetes 2023, 72 DOI: 10.2337/db23-1162-p.Peer-Reviewed Original ResearchAltmetricConceptsK12 programEffects of mentoringProductive academic careerPromote career developmentLetter of intentMentoring communityAcademic careerCareer trajectoriesCareer developmentProgram administratorsPhysician-scientistsRate of physiciansDiversity trainingProgram trainingLeadership CommitteeTraining experienceScientific Review CommitteeDigestive and Kidney DiseasesResearch supportInstitutionsCareerDiabetes InstituteNationwide cohortProgramAdvisory Panel164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
LAFFEL L, DANNE T, TAMBORLANE W, KLINGENSMITH G, NEUBACHER D, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S. 164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo. Diabetes 2023, 72 DOI: 10.2337/db23-164-lb.Peer-Reviewed Original ResearchConceptsHbA1c <Increasing prevalence of childhood overweightGlycemic controlPrevalence of childhood overweightSafety of empagliflozinLinagliptin 5 mgClinically meaningful responseYouth-onset T2DOnset of complicationsBeta-cell functionPost hoc analysisEmpagliflozin groupClinical courseFPG levelsChildhood overweightSGLT2 inhibitorsEmpagliflozinYouth-onsetPlaceboHbA1c changeMeaningful responseHbA1cHigher HbA1cHoc analysisIncreased prevalence
2022
DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice
Doyle EA, Weinzimer SA, Tamborlane W. DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice. The Science Of Diabetes Self-Management And Care 2022, 48: 476-482. PMID: 36129121, DOI: 10.1177/26350106221125699.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsContinuous glucose monitorHigher A1C levelsA1c levelsDKA eventsInsulin pumpPump usersPump-treated patientsRetrospective chart reviewPediatric endocrinology practiceType 1 diabetesInsulin pump usersConcurrent illnessDKA preventionPump patientsDiabetes durationDKA episodesMean A1CChart reviewEndocrinology practiceDKA ratesDKA severityMean ageInsulin omissionMost episodesPatientsCommentary on CDC data showing an increased risk for pediatric diabetes with COVID‐19 infection
Gujral J, Tamborlane W, Nally L. Commentary on CDC data showing an increased risk for pediatric diabetes with COVID‐19 infection. Journal Of Diabetes 2022, 14: 630-632. PMID: 36073304, PMCID: PMC9512767, DOI: 10.1111/1753-0407.13311.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCOVID-19 infectionIncidence of diabetesBody mass indexType of diabetesMortality Weekly ReportCommercial health insurancePrevention's MorbidityMass indexPediatric diabetesViral variantsSocial determinantsDisease controlDiabetesRecent CentersHealth insuranceCDC dataSignificant increaseInfectionWeekly reportsMorbidityIncidenceA Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes
Reiss AL, Jo B, Arbelaez AM, Tsalikian E, Buckingham B, Weinzimer SA, Fox LA, Cato A, White NH, Tansey M, Aye T, Tamborlane W, Englert K, Lum J, Mazaika P, Foland-Ross L, Marzelli M, Mauras N. A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes. Nature Communications 2022, 13: 4940. PMID: 36042217, PMCID: PMC9427757, DOI: 10.1038/s41467-022-32289-x.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHybrid closed-loop insulin delivery systemStandard care groupType 1 diabetesClosed-loop insulin delivery systemWhite matter volumeCare groupPrimary outcomeInsulin delivery systemsMatter volumeFractional anisotropyCognitive AssessmentRigorous glucose controlDiagnosis of T1DClosed-loop groupBetter diabetes controlDiabetes care groupsConcept pilot studyYears of ageAcademic medical centerFunctional brain activityCortical surface areaMonths study durationRandomized participantsDiabetes controlGlucose controlAmerican Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022, 28: 923-1049. PMID: 35963508, PMCID: PMC10200071, DOI: 10.1016/j.eprac.2022.08.002.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsClinical practice guidelinesEvidence-based recommendationsPractice guidelinesGlycemic targetsDiabetes mellitusComprehensive careCare plansEvidence-based clinical practice recommendationsEndocrinology Clinical Practice GuidelineNew evidence-based recommendationsLiterature searchManagement of prediabetesDiabetes care teamDiabetic kidney diseaseClinical practice recommendationsComprehensive care planType 1 diabetesAmerican AssociationCare of personsHealth care professionalsSecondary diabetesBariatric surgeryInsulin therapyClinical evidenceKidney diseaseOnce-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaselineThe obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study
Levitsky LL, Drews KL, Haymond M, Glubitosi-Klug RA, Katz L, Mititelu M, Tamborlane W, Tryggestad JB, Weinstock RS, Group T. The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study. Journal Of Diabetes And Its Complications 2022, 36: 108259. PMID: 36150365, DOI: 10.1016/j.jdiacomp.2022.108259.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsNon-proliferative diabetic retinopathyType 2 diabetesHigh-sensitivity C-reactive proteinObesity paradoxInflammatory biomarkersHDL cholesterolLDL cholesterolInsulin-like growth factor binding protein 1Sensitivity C-reactive proteinGrowth factor binding protein 1Today StudyPresence of retinopathyRelationship of obesityC-reactive proteinPlasminogen activator inhibitor-1Tumor necrosis factor receptor 1Digital fundus photographsNecrosis factor receptor 1Activator inhibitor-1Factor receptor 1Higher BMIObese participantsRisk markersDiabetic retinopathyInterleukin-6SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretion
Clinical Trials
Current Trials
GO MOMs (Glycemic Observation and Metabolic Outcomes in Mothers and Offspring)
HIC ID2000029893RoleSub InvestigatorPrimary Completion Date02/28/2026Recruiting ParticipantsImpact of Hypoglycemia on Brain Ketone and Neurotransmitter Metabolism in Type 1 DM
HIC ID1208010648RoleSub InvestigatorPrimary Completion Date09/29/2022Recruiting ParticipantsGenderBothAge18+ yearsPathway to Prevention
HIC ID2000021339RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting ParticipantsGenderBothAge1 year - 45 years
Academic Achievements & Community Involvement
honor American Diabetes Association Award for Achievements in Clinical Diabetes Research
National AwardAmerican Diabetes AssociationDetails06/08/2017United Stateshonor Career Achievement Award
International AwardInternational Society for Pediatric and Adolescent DiabetesDetails09/17/2014Canadahonor National Award for Career Achievement and Contributions to Clinical and Translational Science
National AwardSociety for Clinical and Translational ScienceDetails06/01/2011United Stateshonor The Best Doctors in America, 2000-2010 Editions America’s Top Doctors, 1st-9th Editions New York Top Doctors, 5-12th Editions
National AwardDetails01/01/2010, 01/01/2000United Stateshonor Outstanding Clinician Physician in Diabetes
National AwardAmerican Diabetes AssociationDetails01/01/2010United States
News & Links
News
- November 01, 2023
Diabetes: Yale's tradition of transforming care
- July 19, 2022
Diabetes Treatment and Research at Yale: 30 Years of Progress
- May 11, 2022
After 37 Years, Tamborlane Stepping Down as Chief of Pediatric Endocrinology & Diabetes; Weinzimer to Succeed as Interim Chief
- July 27, 2021Source: The Cardiology Advisor
Extended-Release Exenatide Approved for Adolescents With T2D
Get In Touch
Contacts
Pediatric Endocrinology & Diabetes
PO Box 208064
New Haven, CT 06520-8064
United States